Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 829-836

  Wood, William A ^a   Lee, Stephanie J ^b   Brazauskas, Ruta ^c   Wang, Zhiwei ^c   Aljurf, Mahmoud D ^d   Ballen, Karen K ^e   Buchbinder, David K ^f   Dehn, Jason ^g   Freytes, Cesar O ^h,i   Lazarus, Hillard M ^j   LeMaistre, Charles F ^k   Mehta, Paulette ^l   Szwajcer, David ^m   Joffe, Steven ⁿ   Majhail, Navneet S ^o,p  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^g NATIONAL MARROW DONOR PROGRAM   (United States)

^h SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k Hematology and Bone Marrow Transplant Sarah Cannon   (United States)

^l UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^m UNIVERSITY OF MANITOBA   (Canada)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^p LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Adolescent and young adults; Allogeneic; Hematopoietic cell transplantation; Survival

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; RECURRENCE RISK; SCHOOL CHILD; YOUNG ADULT; AGE; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899943649     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.021     Document Type: Article

References (24)

1. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin 2007, 57:242-255.
2. Wood W.A., Lee S.J. Malignant hematologic diseases in adolescents and young adults. Blood 2011, 117:5803-5815.
3. Stock W., La M., Sanford B., et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008, 112:1646-1654.
4. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010, 2010:21-29.
5. Kantarjian H.M., O'Brien S. Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens. Blood 2009, 113:1861.
6. Schafer E.S., Hunger S.P. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol 2011, 8:417-424.
7. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
8. Hahn T., McCarthy P.L., Hassebroek A., et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013, 31:2437-2449.
9. Burke M.J., Gossai N., Wagner J.E., et al. Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013, 19:138-142.
10. Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and care imperatives for adolescents and young adults with cancer. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, and the LiveStrong Young Adult Alliance. NIH Publication No. 06-6067, Bethesda, MD (2006) Available at:. http://planning.cancer.gov/library/AYAO_PRG_Report_2006_FINAL.pdf.
11. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
12. Moorman A.V., Ensor H.M., Richards S.M., et al. Prognostic effect of chromosomal abnormalities in childhood B cell precursor acute lymphoblastic leukemia: results from the UK Medical Research Council ALL97/99 randomized trial. Lancet Oncol 2010, 11:429-438.
13. Moorman A.V., Harrison C.J., Buck G.A., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALL XII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007, 109:3189-3197.
14. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985, 53:457-481.
15. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
16. Majhail N.S., Brazauskas R., Hassebroek A., et al. Outcomes of allogeneic hematopoietic cell transplantation for adolescents and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant 2012, 18:861-873.
17. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111:1827-1833.
18. Cornelissen J.J., van der Holt B., Verhoef G.E., et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009, 113:1375-1382.
19. Gupta V., Richards S., Rowe J., et al. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 2013, 121:339-350.
20. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cell versus bone marrow from unrelated donor. N Engl J Med 2012, 367:1487-1496.
21. Lee S.J., Astigarraga C.C., Eapen M., et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:1231-1238.
22. Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN0901). Available at:. Accessed: November 19, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01339910.
23. Marks D.I., Wang T., Perez W.S., et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2012, 116:366-374.
24. Lee S.J., Storer B., Wang H., et al. Providing personalized prognostic information for adult leukemia survivors. Biol Blood Marrow Transplant 2013, 19:1600-1607.